[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Stamelou et al., 2019 - Google Patents

One decade ago, one decade ahead in progressive supranuclear palsy

Stamelou et al., 2019

Document ID
8495805259713607049
Author
Stamelou M
Giagkou N
Höglinger G
Publication year
Publication venue
Movement Disorders

External Links

Snippet

Fifty‐five years have passed from the first description of PSP, but it is in the last decade that there has been a revolutionary change in understanding both clinical and pathophysiological aspects of this disease. Ten years ago, our knowledge about the clinical …
Continue reading at movementdisorders.onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Selkoe The therapeutics of Alzheimer's disease: where we stand and where we are heading
Robinson et al. The development and convergence of co-pathologies in Alzheimer’s disease
Sanyal et al. Lysosome and inflammatory defects in GBA1‐mutant astrocytes are normalized by LRRK2 inhibition
Ofengeim et al. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease
Stamelou et al. One decade ago, one decade ahead in progressive supranuclear palsy
Stutzbach et al. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease
Mikulca et al. Potential novel targets for A lzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
Rauchmann et al. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum
Burns et al. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs
Lippa et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
Devine et al. Parkinson's disease and α‐synuclein expression
Ferencz et al. Genetics and underlying pathology of dementia
Louwersheimer et al. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment
Zhang et al. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model
Sawa et al. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Kovacs et al. Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia
Höglund et al. Molecular biomarkers of neurodegeneration
Moore et al. Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease
Tarawneh et al. Distinguishing Lewy body dementias from Alzheimer’s disease
Panza et al. Disease-modifying therapies for tauopathies: agents in the pipeline
Reynolds A short perspective on the long road to effective treatments for Alzheimer's disease
Asih et al. Clearing the amyloid in Alzheimer’s: progress towards earlier diagnosis and effective treatments–an update for clinicians
Chatterjee et al. Plasma glial fibrillary acidic protein is associated with 18F-SMBT-1 PET: two putative Astrocyte reactivity biomarkers for Alzheimer’s disease
Russell et al. The impact of dementia development concurrent with Parkinson’s disease: a new perspective
Bonomi et al. Cerebrospinal fluid sTREM-2, GFAP, and β-S100 in symptomatic sporadic Alzheimer’s disease: Microglial, astrocytic, and APOE contributions along the Alzheimer’s disease continuum